Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2022

Nov 09, 2022

SELL
$0.25 - $11.7 $1,398 - $65,449
-5,594 Reduced 27.23%
14,946 $3,000
Q2 2022

Aug 11, 2022

SELL
$0.3 - $1.31 $1,145 - $5,002
-3,819 Reduced 15.68%
20,540 $6,000
Q1 2022

May 12, 2022

BUY
$0.61 - $1.84 $4,227 - $12,751
6,930 Added 39.76%
24,359 $34,000
Q4 2021

Feb 11, 2022

SELL
$1.16 - $2.74 $3,138 - $7,414
-2,706 Reduced 13.44%
17,429 $21,000
Q3 2021

Nov 12, 2021

BUY
$2.62 - $5.43 $9,880 - $20,476
3,771 Added 23.04%
20,135 $53,000
Q2 2021

Aug 10, 2021

BUY
$5.06 - $8.15 $82,801 - $133,366
16,364 New
16,364 $87,000
Q1 2021

May 12, 2021

SELL
$6.24 - $9.58 $147,657 - $226,691
-23,663 Closed
0 $0
Q4 2020

Feb 10, 2021

BUY
$6.28 - $8.79 $112,317 - $157,209
17,885 Added 309.54%
23,663 $160,000
Q3 2020

Nov 12, 2020

SELL
$7.5 - $11.11 $990 - $1,466
-132 Reduced 2.23%
5,778 $43,000
Q2 2020

Aug 13, 2020

BUY
$8.33 - $13.79 $49,230 - $81,498
5,910 New
5,910 $62,000
Q1 2020

May 13, 2020

SELL
$3.83 - $8.79 $49,529 - $113,672
-12,932 Closed
0 $0
Q4 2019

Feb 10, 2020

BUY
$3.36 - $4.81 $26,376 - $37,758
7,850 Added 154.47%
12,932 $48,000
Q3 2019

Nov 12, 2019

BUY
$3.57 - $6.58 $18,142 - $33,439
5,082 New
5,082 $19,000
Q4 2018

Feb 06, 2019

SELL
$4.29 - $9.94 $3,427 - $7,942
-799 Closed
0 $0
Q3 2018

Nov 08, 2018

SELL
$9.54 - $13.87 $10,265 - $14,924
-1,076 Reduced 57.39%
799 $8,000
Q2 2018

Aug 14, 2018

BUY
$13.3 - $17.49 $24,937 - $32,793
1,875 New
1,875 $26,000

Others Institutions Holding KALA

# of Institutions
1
Shares Held
1
Call Options Held
0
Put Options Held
0

About Kala Pharmaceuticals, Inc.


  • Ticker KALA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 1,464,160
  • Market Cap $8.67M
  • Description
  • Kala Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies using its proprietary mucus penetrating particles technology for the treatment of eye diseases. The company's product candidates include KPI-012, which is in clinical development stage for the treatment of persistent...
More about KALA
Track This Portfolio

Track Group One Trading, L.P. Portfolio

Follow Group One Trading, L.P. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Group One Trading, L.P., based on Form 13F filings with the SEC.

News

Stay updated on Group One Trading, L.P. with notifications on news.